From: Second primary malignancies after ocular adnexal lymphoma diagnosis
Cancer Site | Time Since Diagnosis | |||||||
---|---|---|---|---|---|---|---|---|
2–11 months | 12–59 months | 60–119 months | 120+ months | |||||
O | O/E (95% CI) | O | O/E (95% CI) | O | O/E (95% CI) | O | O/E (95% CI) | |
All Sites | 42 | 2.07* (1.49–2.79) | 98 | 1.24* (1.01–1.51) | 57 | 0.89 (0.68–1.16) | 82 | 1.2 (0.95–1.48) |
Other Non-Epithelial Skin | 1 | 12.86 (0.33–71.66) | 1 | 3.16 (0.08–17.6) | 1 | 3.53 (0.09–19.69) | 2 | 5.87 (0.71–21.2) |
Female Breast | 3 | 1.12 (0.23–3.27) | 4 | 0.38* (0.1–0.98) | 2 | 0.23* (0.03–0.83) | 10 | 1.15 (0.55–2.11) |
Kidney | 4 | 8.31* (2.26–21.27) | 4 | 2.1 (0.57–5.38) | 3 | 1.89 (0.39–5.52) | 1 | 0.56 (0.01–3.11) |
Cranial Nerves/Other Nervous System | 1 | 109.46* (2.77–609.86) | 0 | 0 (0–103.57) | 0 | 0 (0–131.8) | 1 | 36.03 (0.91–200.74) |
All Lymphatic and Hematopoietic Diseases | 7 | 4.03* (1.62–8.31) | 25 | 3.66* (2.37–5.41) | 15 | 2.64* (1.47–4.35) | 28 | 4.40* (2.92–6.36) |
Lymphoma | 3 | 3.45 (0.71–10.07) | 19 | 5.53* (3.33–8.64) | 10 | 3.48* (1.67–6.4) | 23 | 7.21* (4.57–10.82) |
Hodgkin’s Lymphoma | 0 | 0 (0–75.01) | 0 | 0 (0–19.72) | 2 | 13.60* (1.65–49.11) | 1 | 6.71 (0.17–37.39) |
HL - Nodal | 0 | 0 (0–77.88) | 0 | 0 (0–20.49) | 2 | 14.15* (1.71–51.13) | 1 | 6.99 (0.18–38.92) |
Non-Hodgkin’s Lymphoma | 3 | 3.65 (0.75–10.68) | 19 | 5.85* (3.52–9.14) | 8 | 2.93* (1.27–5.78) | 22 | 7.24* 4.53 10.95 |
NHL - Nodal | 1 | 1.8 (0.05–10.02) | 12 | 5.48* (2.83–9.58) | 1 | 0.55 (0.01–3.06) | 9 | 4.51* (2.06–8.57) |
NHL - Extranodal | 2 | 7.53 (0.91–27.22) | 7 | 6.61* (2.66–13.63) | 7 | 7.70* (3.09–15.86) | 13 | 12.43* (6.62–21.26) |
Leukemia | 3 | 5.18* (1.07–15.14) | 4 | 1.76 (0.48–4.52) | 5 | 2.66 (0.86–6.2) | 3 | 1.42 (0.29–4.16) |
Non-Lymphocytic Leukemia | 1 | 3.43 (0.09–19.08) | 3 | 2.63 (0.54–7.68) | 3 | 3.18 (0.66–9.31) | 2 | 1.91 (0.23–6.91) |
Acute Non-Lymphocytic Leukemia | 1 | 5.39 (0.14–30.02) | 3 | 4.13 (0.85–12.06) | 2 | 3.29 (0.4–11.9) | 1 | 1.46 (0.04–8.13) |
Myeloid and Monocytic Leukemia | 1 | 4 (0.1–22.28) | 3 | 3.06 (0.63–8.94) | 3 | 3.67 (0.76–10.71) | 2 | 2.17 (0.26–7.85) |
Acute Myeloid Leukemia | 1 | 6.41 (0.16–35.74) | 2 | 3.25 (0.39–11.76) | 2 | 3.84 (0.46–13.86) | 1 | 1.67 (0.04–9.3) |